Travis Fleming

Stem cell-like states confer poor outcomes in blood cancer—but what mechanisms drive this and how can they be therapeutically targeted? In our new preprint, we show how a single TF represses one enhancer to maintain a subset of high-risk leukemias: 🧵👇 biorxiv.org/content/10.110…

Joining the Voit Lab is the best decision you will ever make. Go work with Richard if you can!

We at voitlab.org are grateful to @TexasCCF for supporting our work. Thank you also to @dallascowboys @dak, @Jalen8Tolbert, @tonyromo, @TroyAikman for using their platform to raise awareness and funds for pediatric cancer research. youtu.be/KZwX8Mf7n5I

super fun game from the inimitable @ernstschmidd - check it out!

A season to remember, and it's just our beginning. 🔱 #GoTritons

Predictomes, a classifier-curated database of AlphaFold-modeled protein-protein interactions dlvr.it/TJgZXl

Alessandro Donada sat down with @d_pastoors and @tjflemin for a deep dive on their latest AML biology preprints. Watch the #SimplyBlood 🩸 interview today simplyblood.org

In our tests, SPOC outperforms other commonly used metrics in prioritizing biologically relevant interactions in large scale AF-M screens. We used SPOC to score ~40,000 binary pairs across ~300 genome maintenance proteins. View all data and use SPOC on: predictomes.org

Very excited to share that my thesis work is out in Molecular Cell! We trained a Structure and Omics informed Classifier (SPOC) to score binary AlphaFold multimer (AF-M) predictions by structural quality and consistency with experimental omics datasets. cell.com/molecular-cell…

I am grateful to @DamonRunyon @StJude for supporting my work and to @bloodgenes for the mentorship🙏 Very excited to meet my peers / this year’s class at the upcoming meeting! damonrunyon.org/news/entries/8…

Excited to share my analysis of the Cancer Dependency Map! My goal was to systematically identify biomarker - dependency relationships in order to identify new anti-cancer targets and understand how to stratify patients to make those targets clinically useful.

I am grateful to be a part of this amazing group. Thank you to @ASH_hematology for supporting my research and career development! And to my mentor@bloodgenes and @DFBC_PedCare for training me🙏

Excited to share our preprint (@D_Pastoors): "MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia"! biorxiv.org/content/10.110… MECOM is a TF whose overexpression leads to aggressive AML and with an immature phenotype. [1/15]

Wonderful to have this work led by @tjflemin along with other colleagues in our laboratory, as well as great collaborators, out on @biorxivpreprint! Stay tuned for exciting complementary work from @d_pastoors, @DelwelRuud, and co coming soon!